This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Chemed (CHE) Q3 Earnings Expected to Decline
by Zacks Equity Research
Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Chemed (CHE) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Chemed (CHE) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Chemed (CHE) Up 1.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemed (CHE) Upgraded to Buy: Here's Why
by Zacks Equity Research
Chemed (CHE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks.com featured highlights include: Cathay General Bancorp, Bio-Rad Laboratories, Chemed Corp, Materialise and Arbor Realty Trust
by Zacks Equity Research
Zacks.com featured highlights include: Cathay General Bancorp, Bio-Rad Laboratories, Chemed Corp, Materialise and Arbor Realty Trust
5 Stocks to Buy as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like CATY, BIO, CHE, MTLS and ABR.
Here's Why You Should Add Chemed (CHE) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE) on strong segmental growth and raised Roto-Rooter and earnings guidance for 2021.
DaVita (DVA) Beats on Q2 Earnings, Raises 2021 EPS View
by Zacks Equity Research
DaVita's (DVA) strength in dialysis patient service revenues drives its Q2 top line.
PacBio's (PACB) Q2 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
PacBio (PACB) sees strength in Q2 product revenues, led by robust consumable sales.
CVS Health (CVS) Q2 Earnings Beat Estimates, EPS View Up
by Zacks Equity Research
CVS Health (CVS) Q2 adjusted EPS drops year over year on escalating costs and expenses which are putting pressure on margins.
Avanos Medical (AVNS) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Avanos Medical's (AVNS) second-quarter 2021 results gains from strength in Pain Management segment.
Charles River (CRL) Q2 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Robust performance by all three segments drove Charles River's (CRL) revenues in the second quarter.
AmerisourceBergen (ABC) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter results benefit from segmental growth.
Myriad Genetics (MYGN) Q2 Earnings Beat, Gross Margin Rises
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q2 sales despite a challenging business environment.
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Zimmer Biomet (ZBH) sales improve across all its operating segments and geographies on recovery from the pandemic in the months of the second quarter.
Henry Schein (HSIC) Q2 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Strengthening demand in the global dental and medical markets drove Henry Schein's (HSIC) revenues in the second quarter.
Bruker (BRKR) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Bruker (BRKR) reports better-than-expected revenues for the second quarter of 2021 on strong segmental performance driving the top line.
Hill-Rom (HRC) Q3 Earnings Top Estimates, 2021 Guidance Up
by Zacks Equity Research
Hill-Rom (HRC) reports better-than-expected revenues for third-quarter fiscal 2021 with strong segmental performance driving the top line.
Fresenius Medical (FMS) Q2 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across the regions, EMEA, Asia Pacific and Latin America.
Chemed (CHE) Q2 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
Chemed (CHE) reports better-than-expected earnings and revenues with strong Roto-Rooter segment performance driving the top line in second-quarter 2021.
Chemed (CHE) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 3.37% and 0.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Chemed (CHE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Chemed (CHE) Up 4.7% Since Last Earnings Report?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Stocks to Bank on Rebounding Outpatient Home Health Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE and USPH are well-poised to gain from the prospects.